

American Cancer Society
The Lifetime Probability of Developing and Dying from Cancer, 2004-2006*

	MALES			FEMALES		
	Developing % 1 in....	Dying % 1 in....	4	Developing % 1 in....	Dying % 1 in....	5
All Sites†	44.05	22.91	4	37.63	19.78	5
Brain & ons	0.67	0.49	204	0.54	0.39	259
Breast	0.12	0.03	2,983	12.08	2.90	34
Colorectal	5.39	2.18	46	5.03	2.05	49
Esophagus	0.79	0.74	136	0.25	0.22	451
Hodgkin lymphoma	0.25	0.05	1,914	0.21	0.04	2,443
Kidney & renal pelvis	1.80	0.58	173	1.09	0.34	292
Larynx	0.61	0.22	464	0.14	0.05	1,958
Leukemia	1.51	0.98	102	1.08	0.70	141
Liver & intrahepatic bile duct	1.01	0.83	121	0.46	0.48	209
Lung & bronchus	7.73	6.43	16	6.31	4.88	21
Melanoma of skin‡	2.67	0.47	213	1.79	0.23	427
Myeloma	0.72	0.46	219	0.56	0.38	266
Non-Hodgkin lymphoma	2.28	0.90	111	1.92	0.76	132
Oral cavity & pharynx	1.40	0.39	256	0.66	0.19	516
Ovary	NA	NA	NA	1.40	1.07	94
Pancreas	1.38	1.29	78	1.39	1.30	77
Prostate	15.90	2.91	34	NA	NA	NA
Stomach	1.11	0.63	159	0.68	0.42	239
Testis	0.37	0.02	4,941	NA	NA	NA
Thyroid	0.44	0.05	1,972	1.25	0.07	1,378
Urinary bladder§	3.81	0.86	117	1.18	0.34	296
Uterine cervix	NA	NA	NA	0.69	0.24	425
Uterine corpus	NA	NA	NA	2.53	0.53	187

* For those free of cancer at beginning of age interval.

† All sites excludes basal and squamous cell skin cancers and in situ cancers except urinary bladder.

‡ Statistics are for whites.

§ Includes invasive and in situ cancer cases.

NA=Not applicable.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.4.1. Database: "SEER 17 Incidence and Mortality, 2000-2006, with Kaposi Sarcoma and Mesothelioma". National Cancer Institute, 2009.